Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. Inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery. Infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures.
Magnesium is the fourth most plentiful cation in our body. It has antinociceptive effects in animal and human models of pain.
Effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. Inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery.
A major cause of pain after cardiac surgery is the median sternotomy particularly on the first two postoperative days.
The most often used analgesics in these patients are parenteral opioids which can lead to undesirable side-effects as sedation, respiratory depression, nausea, and vomiting.
Infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures.
Magnesium is the fourth most plentiful cation in our body. It has antinociceptive effects in animal and human models of pain.
It has been mentioned in a systematic review that it may be worthwhile to further study the role of supplemental magnesium in providing perioperative analgesia, because this is a relatively harmless molecule, is not expensive and also because the biological basis for its potential antinociceptive effect is promising.
These effects are primarily based on physiological calcium antagonism, that is voltage-dependent regulation of calcium influx into the cell, and noncompetitive antagonism of N-methyl-D-aspartate (NMDA) receptors.
there is a need to evaluate and compare local magnesium with bupivacaine , in comparison to bupivacain ,and other conventional intarvenous analgesics
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| group A | Active Comparator | ( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours |
|
| group B | Active Comparator | bupivacaine 0.125% infusion in the presternum , for 48 hours |
|
| Group C | Active Comparator | will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bupivacain with magnesium sulphate | Drug | will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours |
|
| Measure | Description | Time Frame |
|---|---|---|
| postoperative pain | Vas Scale | 48 hours postoperative |
| Measure | Description | Time Frame |
|---|---|---|
| extubation time | time to separate patient from mechanical ventilation and extubation | 48 hours |
| Fentanyl consumption | total fenatnyl consumption |
Not provided
Criteria:
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emad Kamel Said, MD | Anesthesia departement , Faculty of Medicine , Assiut university | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emad Zarief Kamel Said | Asyut | 71111 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D008278 | Magnesium Sulfate |
| D000779 | Anesthetics, Local |
| D000277 | Adjuvants, Pharmaceutic |
| D003226 | Congresses as Topic |
| D000082 | Acetaminophen |
| D020910 | Ketorolac |
| ID | Term |
|---|---|
| D017616 | Magnesium Compounds |
| D007287 | Inorganic Chemicals |
| D013431 | Sulfates |
| D013464 | Sulfuric Acids |
Not provided
Not provided
pain control in the early postoperative period
Not provided
Not provided
Not provided
| Bupivacaine only | Drug | will receive bupivacain 0.125% infusion in the presternum , for 48 hours |
|
|
| conventional | Drug | only conventional post operative analgesics will be used |
|
|
| 48 hours |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013456 |
| Sulfur Acids |
| D013457 | Sulfur Compounds |
| D000777 | Anesthetics |
| D002492 | Central Nervous System Depressants |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |
| D010592 | Pharmaceutic Aids |
| D004364 | Pharmaceutical Preparations |
| D020313 | Specialty Uses of Chemicals |
| D009938 | Organizations |
| D004472 | Health Care Economics and Organizations |
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D007213 | Indomethacin |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |